• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 5. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849

Recent Advances in the Study of 3-(4-Bromophenyl)-5-methylisoxazole-4-carboxylic acid (CAS: 91182-58-0)

The compound 3-(4-bromophenyl)-5-methylisoxazole-4-carboxylic acid (CAS: 91182-58-0) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This heterocyclic compound, featuring an isoxazole core with a bromophenyl substituent, has been investigated for its role as a key intermediate in the synthesis of biologically active molecules. Recent studies have explored its utility in drug discovery, particularly in the development of anti-inflammatory and anticancer agents.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers demonstrated that derivatives of 3-(4-bromophenyl)-5-methylisoxazole-4-carboxylic acid exhibit potent inhibitory activity against cyclooxygenase-2 (COX-2), an enzyme implicated in inflammation and pain. The compound's unique structural features, including the bromine atom at the para position of the phenyl ring, were found to enhance binding affinity to the COX-2 active site. Molecular docking studies revealed that the bromophenyl group interacts with hydrophobic pockets in the enzyme, while the carboxylic acid moiety forms critical hydrogen bonds with key amino acid residues.

Another significant development was reported in Bioorganic & Medicinal Chemistry Letters, where scientists utilized 91182-58-0 as a building block for the synthesis of novel kinase inhibitors. The study highlighted the compound's versatility in medicinal chemistry, as it served as a scaffold for the development of compounds targeting protein kinases involved in cancer progression. The researchers employed structure-activity relationship (SAR) studies to optimize the biological activity, demonstrating that modifications at the 5-methyl position of the isoxazole ring could significantly alter the selectivity profile of the resulting inhibitors.

Recent advancements in synthetic methodology have also improved access to 3-(4-bromophenyl)-5-methylisoxazole-4-carboxylic acid. A 2024 publication in Organic Process Research & Development described a scalable, green chemistry approach to its synthesis, featuring a one-pot cyclization-oxidation sequence with improved atom economy and reduced environmental impact. This development is particularly important for potential industrial-scale production of pharmaceutical intermediates derived from this compound.

The pharmacokinetic properties of 91182-58-0 derivatives have been the subject of ongoing research. A preclinical study published in European Journal of Pharmaceutical Sciences investigated the metabolic stability and membrane permeability of several analogs. The results indicated that while the parent compound shows moderate metabolic stability, strategic modifications to the carboxylic acid group could enhance both oral bioavailability and blood-brain barrier penetration, expanding potential therapeutic applications to central nervous system disorders.

Looking forward, the unique structural features and demonstrated biological activities of 3-(4-bromophenyl)-5-methylisoxazole-4-carboxylic acid position it as a promising scaffold for future drug discovery efforts. Current research directions include exploration of its potential in targeted protein degradation strategies and as a component of PROTAC molecules. The compound's versatility and the growing body of research supporting its pharmacological relevance suggest it will remain an important focus in medicinal chemistry in the coming years.

• 91569-58-3(5-methyl-3-(o-tolyl)isoxazole-4-carboxylic acid)
• 1104461-65-5(3-(2,6-Dimethylphenyl)-5-methyl-1,2-oxazole-4-carboxylic acid)
• 1136-45-4(5-Methyl-3-phenyl-4-isoxazolecarboxylic Acid)
• 55967-38-9(4-Isoxazolecarboxylicacid, 5-methyl-3-phenyl-, potassium salt (1:1))
• 1119449-35-2(3-(4-Bromophenyl)-5-methylisoxazole-4-carboxaldehyde)
• 876717-65-6(5-Methyl-3-(m-tolyl)isoxazole-4-carboxylic acid)
• 91569-59-4(5-Methyl-3-(4-methylphenyl)isoxazole-4-carboxylic acid)
• 7035-83-8(3-(4-Aminophenyl)-5-methylisoxazole-4-carboxylic acid)
• 954230-26-3(Ethyl 3-(4-bromophenyl)-5-methyl-1,2-oxazole-4-carboxylate)
• 91182-60-4(5-(4-bromophenyl)-3-methyl-1,2-oxazole-4-carboxylic acid)